European Psychiatry - Volume 33 - March 2016

124 / 812

S120 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348
5 Hospital Universitari Germans Trías i Pujol, IGTP, Universitat
Autònoma de Barcelona, Pharmacology, Barcelona, Spain
∗ Corresponding author.
Introduction In recent years, the increasing use tendency of NPS
has motivated both awareness and concern about their identifica-
tion and potential harmfulness. Synthetic cathinones represent a
significant proportion of the NPS available and methylone is one of
the most frequently found in Europe.
Objectives The aim of the present study is to determine methy-
lone presence and characteristics from the samples analyzed by
Energy Control between the years 2009 and 2015 in Spain.
Methods From all 21,198 samples analyzed from august 2009 to
august 2015, only those in which methylone was found are stud-
ied (n = 140). The samples have been analyzed by Energy Control, a
spanish harm-reduction NGO that offers to users the possibility of
analyzing the substances they intend to consume. The analysis is
done by gas chromatography–mass spectrometry.
Results From the 140 samples containing methylone, 87 were
handled asmethylone, 20 asMDMA, 8 as other synthetic cathinones
and 25 as other substances. The peak of consume was registered in
2011 with 41 samples then the number decreased until 10 samples
in 2015.
Conclusions Results suggest that methylone is most frequently
handled as methylone or as MDMA and that its consumption could
be decreasing. Further pharmacokinetic, pharmacodynamic, clini-
cal and epidemiological studies should be conducted to enhance the
knowledge not only about methylone consumption, but also about
synthetic cathinones in general in order to assess their potential
risk and study the complications and its management.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Acknowledgements Supported by grants of ISCIII-FEDER-(RTA
RD12/0028/0009), and The European Commission-
(Drug Prevention and Information Programme 2014-16,
JUST/2013/DPIP/AG/4823, EU-MADNESS project). L. Galindo is
a Rio-Hortega-fellowship-(ISC-III;-CM14/00111).
EW12
Leptin and ghrelin levels in alcohol
dependent patients and their
relationship with withdrawal and
craving
S. Mehta ∗, A. Baruah , S. Khattri , S. Das , P. Avinash
1 SMI, Psychiatry, Dehradun, India
2 LGB Regional Institute of Mental Kealth, Psychiatry, Tezpur, India
∗ Corresponding author.
Introduction Association between leptin and ghrelin plasma lev-
els and alcohol craving have been found in few studies.
Objectives To search this correlation in a different population
while comparing levels of these hormones with healthy individuals
and also to study this correlation with respect to hyper-excitable
state of alcohol withdrawal.
Aim To assess leptin and ghrelin levels after 3weeks of absti-
nence in alcohol-dependent patients.
Methods Twenty-five indoor patients fulfilling the alcohol
dependence criteria were assessed for withdrawal symptoms and
craving for alcohol. Leptin and ghrelin levels were measured on 1st
day, at the end of 1st week, at the end of 3rd week of stopping
alcohol. Withdrawal was assessed using CIWA-A at day 1 and day
7, craving was assessed using PENN’s scale of craving at the end
of week 1 and week 3. Control group consisted of 15 first-degree
relatives.
Results It was found that leptin [t (38) = 2.95, P = 0.005] and
ghrelin [t (38) = 2.56, P = 0.015] were significantly higher in
alcohol-dependent patients. Levels of hormones had no signifi-
cant correlation with alcohol withdrawal scores but had positive
correlation with craving scores after abstinence.
Conclusions Study shows that leptin and ghrelin, known for bal-
ancing the energy homeostasis of body, also seem to play role in
pathways of drug dependence and craving. This relation is inde-
pendent of stress hormone axis as leptin and ghrelin levels are not
correlated with withdrawal scores, which is an indicator of stress
hormone axis activation during alcohol withdrawal.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW13
Presence and evolution of a new
psychoactive tryptamines branch
Á. Palma Conesa ∗, L. Galindo Guarin , M. Grifell Guardia ,
P. Quintana Mathe , C. Gil Lladanosa , I. Fornís Espinosa ,
M. Ventura Vilamala , M. Torrens Melich ,
M. Farré Albaladejo , M.F. Fonseca Casals
1 Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar,
Psychiatry, Barcelona, Spain
2 Institut Hospital del Mar d’Investigacions Mèdiques, IMIM, Parc de
Salut Mar, Psychiatry, Barcelona, Spain
3 Energy Control, Asociación Bienestar y Desarrollo, Energy Control,
Barcelona, Spain
4 Universitat Autònoma de Barcelona, Psychiatry, Barcelona, Spain
5 Servei de Farmacología Clínica, Hospital Germans Trías i Pujol,
Clinical Farmacology, Barcelona, Spain
∗ Corresponding author.
Introduction New psychoactive substances (NPS) are substances
that have recently appeared on the market and are not under
international control. NPS use is experiencing an unprecedented
increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive
tryptamines and their effects may differ from those of other psy-
choactive tryptamines.
Objective To explore the presence of DiPT, 4-HO-DiPT and 4-AcO-
DiPT from samples delivered to and analyzed by Spanish harm
reduction service Energy Control.
Materials and methods All samples analyzed from 2009 to 2014
delivered as DiPT, 4-HO-DiPT and 4-AcO-DPT or containing these
substances. Analysis was performed by gas chromatography–mass
spectrometry.
Results From 17,432 samples, 4-HO-DiPT was found in 16, deliv-
ered as 4-HO-DiPT (6); 4-AcO-DiPT (7); DiPT (1); 4-AcO-DMT (1)
and cocaine (1). 4-AcO-DiPT was found in 16, delivered as 4-AcO-
DiPT (12); 5-MeO-DMT (1); 5-MeO-DiPT (1); 4-AcO-DMT (1) and
cocaine (1). Only 4 samples contained DiPT, all presented as DiPT.
Nine samples contained both 4-AcO-DiPT and 4-HO-DiPT. Dur-
ing the years of study, 4-HO-DiPT deliverance was increasing (4
samples in 2014) while deliverance of 4-AcO-DiPT and DiPT was
decreasing (1 sample in 2014).
Conclusions Increasing 4-HO-DiPT presence could translate a
progressive replacement of 4-AcO-DiPT and DiPT recreational use.
Clinical relevance comes from its growing use and the absence of
scientific evidence on humans, therefore relying on users subjective
experience to predict the effects.
Disclosure of interest The authors declare that they have no com-
peting interest.
Acknowledgement Supported in part by grants of Instituto de
Salud Carlos III-FEDER (RTA RD12/0028/0009), and The European
Commission (Drug Prevention and Information Programme 2014-
16, contract no.: JUST/2013/DPIP/AG/4823, EU-MADNESS project).
Liliana Galindo is a Rio Hortega fellowship (ISC-III; CM14/00111).